Breast Cancer and Osteoporosis – Management of Cancer Treatment-Induced Bone Loss in Postmenopausal Women with Breast Cancer

Breast care

Peyman Hadji¹  Matthias Kalder¹ 

[1] aDepartment of Obstetrics and Gynecology, Philipps University of Marburg, Germany

关键词: Osteoporosis;    Breast cancer;    Bone mineral density;    Aromatase inhibitor-induced bone loss;    AIBL;    Cancer treatment-induced bone loss;    CTIBL;   

DOI  :  10.1159/000368843

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

The incidence of breast cancer (BC) in postmenopausal women is continuously rising. Due to early diagnosis and various treatment designs, the long-term clinical outcome has improved. Frequent settings are chemotherapy as well as endocrine treatment. Both have proven to interfere with bone health resulting in cancer treatment-induced bone loss (CTIBL). Whereas chemotherapy is associated with increased bone resorption, aromatase inhibitor (AI) therapy reduces residual estrogen and is associated with decreased bone mineral density. Independent of the AI administered, the loss of bone mineral density is twice as high compared to healthy postmenopausal women. As a consequence of CTIBL, both chemotherapy and AI treatment can lead to a significantly increased fracture risk. Therefore, several guidelines have emerged for the management of CTIBL in women with BC, including strategies to identify and treat those at high risk for fractures. Further research on tracking guideline adherence examining the feasibility and practicability of guideline implementation to bridge the gap between determined scientific best evidence and applied best practice is needed to adjust these guidelines in the future.

【 授权许可】

Unknown